Table 1

Clinical data in RA patients with renal involvement

PatientAge/sexDisease duration1-150 Drug/duration1-150 RF (IU/ml) initial/nephritisUrine RBCDaily proteinIgG/A/M (mg/dl)BUN/Cr (mg/dl)Renal biopsy
158/M16MD-PC/9M1510/302–45.11712/292/15317/1.1MGN
254/F21MGold/1285mg945/300–13.81980/178/10818/1.2MGN
351/M102MGold/1310mg556/302–33.51690/250/10320/1.2MGN
463/F42MPla+Sul/38M112/962–35.42370/694/18417/0.8MGN
538/F46MMTX+Sul/36M1450/8830–402.61741/890/26612/0.7IgA Nephropathy
667/M80MPla+Sul/80M994/125–63.52980/652/18535/1.2MGN
736/F44MMTX/40M552/405–61.72190/778/24725/0.9FPGN
862/M64MMTX+Sul/26M1280/422–35.91280/670/28818/0.9MGN
949/F216MCHD/216M668/434–51.31615/156/17020/1.6 FSGS
1066/F108MCHD/108M434/1644–52.32100/221/12333/3.5FSGS
1145/F96MCHD/96M223/36.43–40.91800/199/18850/7.0CRF
1251/F106MCHD/106M884/3204–61.11921/229/10162/8.6CRF
1364/M72MCHD/72M234/10.14–61.51700/376/8963/3.3TIN
1476/M228MCHD/228M280/33.22–51.41832/288/11248/4.5TIN
  • 1-150 Duration (months) since diagnosis of RA and prescription of disease modified antirheumatic drugs until diagnosis of nephropathy, total cumulative dose of gold salt was calculated. Persistent renal insufficiency was noted in patients 4−14. No abnormality in liver function and no significant drug reaction was noted. MTX: methotrexate; Sul: sulphasalazine; D-PC: D-penicillamine; Gold: gold salt intramuscular weekly injection; Pla: hydroxychloroquine; CHD: Chinese herb drug; MGN: membranous glomerulonephritis; FPGN: focal proliferative glomerulonephritis; FSGS: focal segmental global sclerosis; CRF: chronic renal failure in uraemic stage; TIN: tubulointerstitial nephritis; urine RBC as number/HPF and daily urine protein as g/24 h.